A phase one trial aimed to investigate whether chronic use of oral topotecan as a single agent suppresses the expression of HIF-1α and angiogenesis in metastatic tumors with the overexpression of HIF-1α (US National Library of Medicine, 2017c). Here, HIF1A is linked to metastatic neoplasm.